Company Encyclopedia
View More
name
EC HEALTHCARE
02138.HK
EC Healthcare provides medical and healthcare services in Hong Kong, Macau, Mainland China, and Taiwan. It operates through Medical; Aesthetic Medical and Beauty and Wellness; and Veterinary and Other segments. The company offers health checkups and screening, vaccinations, laboratory testing, imaging diagnostics, dental care, and pain management services; quasi-medical and chiropractic services; and aesthetic medical, beauty, haircare, and wellness services. It also provides general and family medicine, musculoskeletal health, eye care, fertility and women’s health, men’s and children’s health, digestive health, chronic disease management, Chinese and sports medicine, corporate medicine and work rehabilitation, preventive screening, rehabilitation and homecare, heart and vascular health, oncology and cancer, and allergies and immunology services.
34.22 B
02138.HKMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
D
Specialized Consumer ServicesIndustry
Industry Ranking21/27
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-8.91%D
    • Profit Margin-4.04%D
    • Gross Margin30.19%C
  • Growth ScoreD
    • Revenue YoY-1.68%D
    • Net Profit YoY-782.39%E
    • Total Assets YoY-6.44%D
    • Net Assets YoY-8.23%D
  • Cash ScoreD
    • Cash Flow Margin-2476.41%E
    • OCF YoY-1.68%D
  • Operating ScoreB
    • Turnover0.8B
  • Debt ScoreD
    • Gearing Ratio56.14%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    EC Healthcare Schedules Board Meeting to Review Interim Results

    EC Healthcare has announced a board meeting on 28 November 2025 to review interim results for the six months ending 30 September 2025 and discuss potential interim dividends. This meeting will provide insights into the company's financial health and potential returns for stakeholders. The latest analyst rating for EC Healthcare stock is a Hold with a HK$0.50 price target. The company operates in the healthcare industry and is listed on the Hong Kong Stock Exchange.

    Tip Ranks·
    HK
    02138
    -3.23%
    Tip Ranks·
    HK
    02138
    -3.23%

    EC Healthcare (HKG:2138) Top Key Executive Chi Fai Tang's holdings dropped 15% in value as a result of the recent pullback

    EC Healthcare's top executive, Chi Fai Tang, saw a 15% drop in the value of his holdings following a recent pullback in share price. He holds 61% of the company, indicating significant insider ownership, which can influence company decisions. Institutional investors own a notable stake, but there is no analyst coverage, suggesting limited market awareness. The general public holds 29% of shares, allowing some influence over company policies. Despite the insider ownership being a positive sign, there are concerns, including two warning signs identified for the company.

    Simplywall·
    HK
    02138
    -3.23%
    Simplywall·
    HK
    02138
    -3.23%

    Understanding the Market | EC HEALTHCARE rises over 18%, accumulating more than 70% increase in the past three days. The company previously reached a strategic cooperation with Yimai Yangguang

    EC HEALTHCARE rose over 18% again, with a cumulative increase of over 70% in the last three trading days. As of the time of writing, it rose 10.1%, trading at HKD 1.09, with a transaction volume of HKD 14.2141 million. In terms of news, in May this year, Yimai Sunshine and EC HEALTHCARE held a grand strategic cooperation signing ceremony in Hong Kong, officially establishing the "Yimai EC HEALTHCARE Technology Alliance," and announced the joint creation of a "centralized procurement + global distribution" dual-engine supply chain platform. Based on the strategic consensus of "gene complementarity and resource synergy," the two parties will establish a joint venture to integrate Yimai Sunshine's core advantages in medical imaging equipment, supply chain of consumables, and departmental operation management with EC HEALTHCARE's channel resources in the Hong Kong, Macau, and overseas markets, building a global medical technology supply chain platform. Public information shows that EC HEALTHCARE is the largest non-hospital medical service supplier in Hong Kong, focusing on precision and preventive medicine, and is committed to becoming a leading one-stop health ecosystem. The company provides comprehensive medical services, including health checks, vaccinations, laboratory testing, imaging diagnostics, primary care, specialist consultations, dental care, and pain management

    Zhitong·
    HK
    02138
    -3.23%
    Zhitong·
    HK
    02138
    -3.23%

    EC Healthcare Publishes 2024/25 Annual Report

    EC Healthcare has published its annual report for 2024/25, highlighting significant business updates and financial performance. The company implemented cost optimization measures, including a reduction of 613 staff and renegotiation of rental rates for 137,000 sq ft of service space, leading to improved rent-to-sales ratios and reduced overhead costs. EC Healthcare is committed to high service standards, sustainability, and community outreach, and has established a Medical Advisory Board to uphold medical governance standards.

    Reuters·
    HK
    02138
    -3.23%
    Reuters·
    HK
    02138
    -3.23%

    EC HEALTHCARE: Ma Qingnan appointed as a member of the nomination committee

    According to the Zhitong Finance APP, EC HEALTHCARE announced that the company's non-executive director, Liang Yangshidi, and the company's independent non-executive director, Ma Qingnan, have been appointed as members of the company's nomination committee, effective from June 23, 2025

    Zhitong·
    HK
    02138
    -3.23%
    Zhitong·
    HK
    02138
    -3.23%